Tharimmune, Inc.·4

Oct 8, 4:10 PM ET

Appajosyula Sireesh 4

4 · Tharimmune, Inc. · Filed Oct 8, 2024

Insider Transaction Report

Form 4
Period: 2024-08-09
Transactions
  • Purchase

    Common Stock

    2024-10-08$1.93/sh+5,000$9,65016,364 total
Holdings
  • Common Stock

    (indirect: See footnote)
    38,889
  • Common Stock

    (indirect: See footnote)
    304
Footnotes (1)
  • [F1]38,889 shares of common stock are held indirectly by Highpoint Pharmaceuticals, LLC and 304 shares of common stock are held by Channel BioConsulting LLC. The Reporting Person is the managing member of each of Highpoint Pharmaceuticals, LLC and Channel BioConsulting LLC and in such capacity has the right to vote and dispose of the securities held by such entities.

Documents

1 file
  • 4
    ownership.xmlPrimary